Ranbaxy launches Ran-Tamsulosin Hydrochloride caps

RELATED NEWS Fortis Health ties up with US hearing aid maker Starkey Ranbaxy settles Flomax case dispute Ranbaxy Lab gains further ground Ranbaxy granted favorable decision by Federal Patent Court ALSO READ See latest News about Ranbaxy Labs See previous management interviews See what other Experts & Brokerages are saying about Ranbaxy Labs Ranbaxy Labs BSE | NSE 13/02/12 Are Mutual Funds betting on Ranbaxy Labs?

Ranbaxy Laboratories Limited (RLL), announced today that the Company has received approval in Canada to manufacture and market Tamsulosin Hydrochloride Capsules 0.4 mg from Health Canada, Therapeutic Products Directorate (TPD).  This product has proven to be bio-equivalent to Flomax^® Capsules which is indicated for the treatment of Benign Prostatic Hyperplasia (BPH).  The total market for both generic and brand Tamsulosin Hydrochloride Capsules in Canada is CAD $22 million (IMS-MAT: March 2007).

 

"We are pleased to receive this approval from TPD for Tamsulosin Hydrochloride Capsules that will expand Ranbaxy's expanding product portfolio of accessible and affordable generic product offerings.  We are also quite proud of the fact that this formulation was fully developed within our parent company Ranbaxy Laboratories Limited, which further demonstrates the capabilities and competencies of the Ranbaxy organization.  This is the fourth product to be added to our product portfolio through this pathway in 2007.   RPCI's Sales Team will be offering Ran-Tamsulosin immediately under the Ranbaxy label in all of the Canadian provinces that now provides another option to pharmacist for this molecule, that will be of benefit to both patients and the Canadian Health Care system," said Paul Drake, President, Ranbaxy Pharmaceuticals Canada Inc. (RPCI), Canada.

  

Sourced From: Ranbaxy Laboratories Ltd